Monitor Closely: Follow up with clients every two to three weeks to adjust the dosage as needed
Based on Phase 2 trial data, nausea associated with retatrutide is most common during the early weeks of treatment or following each dose increase, and typically diminishes over time as the body adjusts to the medication
Less common but clinically significant adverse effects include injection site reactions (erythema, pruritus, or induration), fatigue, and hypoglycaemiaparticularly when tirzepatide is used in combination with insulin or sulphonylureas
GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonism: Working in concert with GLP-1, GIP activation further augments insulin release and contributes to feelings of satiety
Tirzepatide (available as Mounjaro or Zepbound) : Tirzepatide is a medication used for both type 2 diabetes and obesity management
While everyone will be affected at different stages, this is a rough timeline of what to expect